Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Gastrocnemius muscle satellite cell abundance (NR/resveratrol vs. placebo and NR vs. placebo) |
Investigators will perform calf muscle biopsies to determine whether among participants with PAD, those randomized to NR + resveratrol and NR alone have increased satellite cell abundance compared to the placebo group. |
Baseline to 6-month follow-up |
|
Other |
NAD+ abundance in gastrocnemius muscle (NR/Resveratrol vs. placebo and NR vs. placebo) |
Investigators will perform calf muscle biopsies to determine whether among participants with PAD, those randomized to NR + resveratrol and NR alone have increased calf muscle NAD+ abundance, compared to the placebo group. |
Baseline to 6-month follow-up |
|
Other |
Muscle fiber phenotype in gastrocnemius muscle (NR/Resveratrol vs. placebo and NR vs. placebo) |
Investigators will perform calf muscle biopsies to determine whether among participants with PAD, those randomized to NR + resveratrol and NR alone have improved muscle fiber phenotype, compared to the placebo group. |
Baseline to 6-month follow-up |
|
Other |
Walking Impairment Questionnaire (WIQ) speed and stair climbing score (NR alone vs. placebo) |
Among participants with PAD, investigators will determine whether NR alone improves the WIQ speed and stair climbing score at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Other |
Short-Form Physical Functioning (SF-36) score (NR alone vs. placebo) |
Among participants with PAD, investigators will determine whether NR alone improves the WIQ speed and stair climbing scores and the Short-Form Physical Functioning score at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Other |
Walking Impairment Questionnaire (WIQ) speed and stair climbing score (NR/resveratrol vs. placebo) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves the WIQ speed and stair climbing scores at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Other |
Short-Form Physical Functioning (SF-36) score (NR/resveratrol vs. placebo) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves the Short-Form Physical Functioning score at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Other |
Walking Impairment Questionnaire (WIQ) speed and stair climbing score (NR/resveratrol vs. NR alone) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves the WIQ speed and stair climbing score at 6-month follow-up, compared to NR alone. |
Baseline to 6-month follow-up |
|
Other |
Short-Form Physical Functioning (SF-36) score (NR/resveratrol vs. NR alone) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves the WIQ speed and stair climbing scores and the Short-Form Physical Functioning score at 6-month follow-up, compared to NR alone. |
Baseline to 6-month follow-up |
|
Other |
Walking Impairment Questionnaire (WIQ) speed and stair climbing score (NR/resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group) have greater improvement in the Walking Impairment Questionnaire (WIQ) speed and stair climbing score at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Other |
Short-Form Physical Functioning (SF-36) score (NR/resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group) have greater improvement in the Short-Form Physical Functioning score at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Primary |
Six-minute walk distance (NR alone vs. placebo) |
Among participants with PAD, investigators will determine whether NR alone improves six-minute walk distance at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Primary |
Six-minute walk distance (NR/resveratrol vs. placebo) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Six-minute walk distance (NR alone vs. placebo) |
Among participants with PAD, investigators will determine whether NR alone improves six-minute walk performance at 3-month follow-up, compared to placebo. |
Baseline to 3-month follow-up |
|
Secondary |
Six-minute walk distance (NR/resveratrol vs. placebo) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 3-month follow-up, compared to placebo. |
Baseline to 3-month follow-up |
|
Secondary |
Six-minute walk distance (NR/resveratrol vs. NR alone) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 3-month follow-up, compared to NR alone. |
Baseline to 3-month follow-up |
|
Secondary |
Six-minute walk distance (NR/resveratrol vs. NR alone) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 6-month follow-up, compared to NR alone. |
Baseline to 6-month follow-up |
|
Secondary |
Maximal treadmill walking time (NR alone vs. placebo) |
Among participants with PAD, investigators will determine whether NR alone improves maximal treadmill walking time at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Walking Impairment Questionnaire (WIQ) distance score (NR alone vs. placebo) |
Among participants with PAD, investigators will determine whether NR alone improves the WIQ distance score at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Physical activity (NR alone vs. placebo) |
Among participants with PAD, investigators will determine whether NR alone improves physical activity at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Maximal treadmill walking time (NR/resveratrol vs. placebo) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves maximal treadmill walking time at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Walking Impairment Questionnaire (WIQ) distance score (NR/resveratrol vs. placebo) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves the WIQ distance score at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Physical activity (NR/Resveratrol vs. placebo) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves physical activity at 6-month follow-up, compared to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Maximal treadmill walking time (NR/resveratrol vs. NR alone) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves maximal treadmill walking time at 6-month follow-up, compared to NR alone. |
Baseline to 6-month follow-up |
|
Secondary |
Walking Impairment Questionnaire (WIQ) distance score (NR/resveratrol vs. NR alone) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves the Walking Impairment Questionnaire (WIQ) distance score at 6-month follow-up, compared to NR alone. |
Baseline to 6-month follow-up |
|
Secondary |
Physical activity (NR/Resveratrol vs. NR alone) |
Among participants with PAD, investigators will determine whether NR combined with resveratrol improves physical activity at 6-month follow-up, compared to NR alone. |
Baseline to 6-month follow-up |
|
Secondary |
Six-minute walk distance (NR/Resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in six-minute walk distance, compared to those randomized to placebo. |
Baseline to 3-month follow-up |
|
Secondary |
Six-minute walk distance (NR/Resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in six-minute walk distance, compared to those randomized to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Maximal treadmill walking time (NR/resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in maximal treadmill walking time, compared to those randomized to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Walking Impairment Questionnaire (WIQ) distance score (NR/resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in WIQ distance score, compared to those randomized to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Physical Activity (NR/resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in physical activity, compared to those randomized to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
NAD+ Abundance in gastrocnemius muscle (NR/resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in NAD+ abundance, compared to those randomized to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Satellite Cell Abundance in gastrocnemius muscle (NR/resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in satellite cell abundance, compared to those randomized to placebo. |
Baseline to 6-month follow-up |
|
Secondary |
Gastrocnemius Muscle Fiber Phenotype(NR/resveratrol or NR alone vs. placebo) |
Participants with PAD who received NR alone and those who received NR + resveratrol will be combined into one group and compared to the group receiving placebo, to determine whether NR alone or NR+ resveratrol (combined group)have greater improvement in muscle fiber phenotype, compared to those randomized to placebo. |
Baseline to 6-month follow-up |
|